Traws Pharma Files 2025 Proxy Statement

TL;DR

Traws Pharma (fka Onconova) dropped its 2025 proxy statement. Standard governance stuff.

AI Summary

Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed a Definitive Proxy Statement (DEF 14A) on February 6, 2025, for the fiscal year ending December 31, 2025. The company, located in Newtown, PA, operates in the Pharmaceutical Preparations industry. This filing is a standard proxy statement related to corporate governance and shareholder matters.

Why It Matters

This filing provides shareholders with essential information regarding the company's governance, executive compensation, and voting matters, which are crucial for informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which is a standard disclosure document for public companies and does not inherently indicate new risks.

Key Players & Entities

• Traws Pharma, Inc. (company) — Registrant
• Onconova Therapeutics, Inc. (company) — Former company name
• 20250206 (date) — Filing date
• 12 PENNS TRAIL, NEWTOWN, PA 18940 (address) — Company business address

FAQ

Key Financial Figures

• $0.01 — g shares of our common stock, par value $0.01 per share ("Common Stock"), upon exerci
• $5.103 — The purchase price per Class A Unit was $5.103 and the purchase price per Class B Unit
• $5.093 — the purchase price per Class B Unit was $5.093. The offering closed on December 31, 20
• $20 m — eceived gross proceeds of approximately $20 million, before deducting placement agent

Filing Documents

• tm254092-3_def14a.htm (DEF 14A) — 205KB
• lg_trawspharma-4clr.jpg (GRAPHIC) — 12KB
• px_24trawsproxy01page01-bw.jpg (GRAPHIC) — 224KB
• px_24trawsproxy01page02-bw.jpg (GRAPHIC) — 168KB
• 0001104659-25-010117.txt ( ) — 701KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15 WHERE YOU CAN FIND ADDITIONAL INFORMATION 17 OTHER MATTERS 17 i TABLE OF CONTENTS Traws Pharma, Inc. 12 Penns Trail Newtown, PA 18940 USA (267) 759-3680 PROXY STATEMENT SPECIAL MEETING OF STOCKHOLDERS TO BE HELD FEBRUARY 17, 2025 GENERAL INFORMATION This Proxy Statement is furnished to stockholders of Traws Pharma, Inc., a Delaware corporation ("we," "us," or the "Company"), in connection with the solicitation by our Board of Directors of proxies for use at our Special Meeting of Stockholders (the "Special Meeting") to be held at 9:00 a.m. Eastern Time on Monday, February 17, 2025, and at any postponement(s) or adjournments thereof. The Special Meeting will be held virtually, via live webcast at www.virtualshareholdermeeting.com/TRAW2025SM. At the Special Meeting, stockholders will be asked to consider and vote upon: 1. A proposal to approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of more than 19.99% of the outstanding shares of our common stock, par value $0.01 per share ("Common Stock"), upon exercise of the Pre-Funded Warrants and Series A Warrants issued in a private placement on December 31, 2024 ("Proposal No. 1"); 2. A proposal to approve, in accordance with Nasdaq Listing Rule 5635(c), the issuance of shares of our Common Stock upon exercise of the Pre-Funded Warrants and Series A Warrants issued to certain insiders in a private placement on December 31, 2024 ("Proposal No. 2"); and 3. A proposal to approve the adjournment of the Special Meeting to another place, or a later date or dates, if necessary or appropriate, to solicit additional proxies in the event we have not received sufficient votes in favor of either of the foregoing proposals ("Proposal No. 3"). After careful consideration, our Board of Directors has approved the proposals set forth above and recommends that our stockholders vote "FOR" each of such proposals.

View Full Filing

View this DEF 14A filing on SEC EDGAR